Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NADK | O95544 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.42 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.39 |
| ▸ | HSPA8 | P11142 | 2/20 | 0.39 |
| ▸ | AMD1 | P17707 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106678 | 1.00 | NADK (0.50) | NADKADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL1135253 | 0.90 | AMD1 (0.49) | HSPA5HSPA8AMD1RXFP1 | |
| SCHEMBL1096911 | 0.90 | AMD1 (0.49) | HSPA5HSPA8AMD1RXFP1 | |
| SCHEMBL7257500 | 0.86 | ALDH1A1 (0.53) | NADKADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL1098546 | 0.84 | GAPDH (0.55) | NADKADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL1097695 | 0.84 | GAPDH (0.46) | NADKHSPA5HSPA8AMD1RXFP1 | |
| SCHEMBL1096954 | 0.82 | ADORA3 (0.48) | NADKADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL1096847 | 0.82 | TRPM2 (0.52) | NADKHSPA5HSPA8AMD1RXFP1 | |
| SCHEMBL13986314 | 0.82 | NADK (0.44) | NADKADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL6762689 | 0.81 | ADORA1 (0.50) | NADKADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765844-B1 | PURINE NUCLEOTIDE DERIVATIVES | SOLVELL AS (NO) | 2014-07-30 | — | — | EP | disclosed |
| US-8153609-B2 | Purine nucleotide derivatives | LAURAS AS (NO) | 2012-04-10 | — | — | US | disclosed |
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20080293665-A1 | Purine Nucleotide Derivatives | LAURAS AS (NO) | 2008-11-27 | — | — | US | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | NADK 88/4885ADORA2A 98/4885ADORA1 77/4885 |
| US-20080293665-A1 | Purine Nucleotide Derivatives | CGAS, PDE8A, PDE7A | NADK 301/4885ADORA2A 15/4885ADORA1 46/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | NADK 103/4885ADORA2A 162/4885ADORA1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.